6 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34268530 | An update on acalabrutinib to treat chronic lymphocytic leukemia. | 2021 Jul | 1 |
2 | 34275396 | Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. | 2021 Sep | 1 |
3 | 31915195 | Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. | 2020 Mar | 1 |
4 | 33093947 | ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. | 2020 | 1 |
5 | 30089638 | Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. | 2018 Oct | 1 |
6 | 28642301 | The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. | 2017 Oct | 1 |